In re Interneuron Pharmaceuticals Litigation

188 F.R.D. 3, 44 Fed. R. Serv. 3d 1179, 1999 U.S. Dist. LEXIS 8948, 1999 WL 395340
CourtDistrict Court, D. Massachusetts
DecidedJune 3, 1999
DocketNo. Civ.A. 97-12254-REK
StatusPublished
Cited by5 cases

This text of 188 F.R.D. 3 (In re Interneuron Pharmaceuticals Litigation) is published on Counsel Stack Legal Research, covering District Court, D. Massachusetts primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re Interneuron Pharmaceuticals Litigation, 188 F.R.D. 3, 44 Fed. R. Serv. 3d 1179, 1999 U.S. Dist. LEXIS 8948, 1999 WL 395340 (D. Mass. 1999).

Opinion

PRACTICE AND PROCEDURE ORDER NO. 9 AND MEMORANDUM IN EXPLANATION

KEETON, District Judge.

Memorandum in Explanation of Order No. 9

I. Introduction

At the hearing of record on March 18, 1999, the court, in an order designated as Practice and Procedure Order No. 7, denied the Defendants’ Motion to Vacate Practice and Procedure Order No. 6 (Docket No. 54) denying Defendants’ Motion to Dismiss (Docket No. 30) without prejudice to the filing at an appropriate time a motion for summary judgment raising essentially the same substantive law issues.

Also, at that hearing the court allowed plaintiffs time to file a further submission bearing upon the motion for class certification and opposition to it, and set a schedule for a responsive submission by defendants and for a Case Management Conference on the matter. The court stated orally on the record tentative views on some of the issues bearing on class certification, and reasons for them.

With the purpose of contributing to sharpening the focus on potentially decisive issues, on March 22, 1999 the court issued Practice and Procedure Order No. 8 and Memorandum in Explanation (Docket No. 62), summarizing and supplementing the oral statement of tentative views'made on March 18 and reasons for them. That order set a schedule for additional filings.

Now before the court, in additional filings, are the following:

(1) Plaintiffs’ Supplemental Memorandum in Support of Class Certification (Docket No. 65, filed April 12, 1999), with Affidavit of Frank C. Dorkey and Attachments A-D (Docket No. 66, filed April 12, 1999); and
(2) Defendants’ Supplemental Memorandum of Law in Opposition to Plaintiffs’ Motion for Class Certification (Docket No. 68, filed May 3, 1999) and Appendix of Exhibits A-0 (Docket No. 69, filed May 3, 1999).

II. Background

. Plaintiffs brought this class action against defendants alleging various securities-fraud claims. The controversy arises from defendants alleged scheme and course of conduct to defraud purchasers of the common stock of Interneuron by omitting and/or misrepresenting material information concerning the defendants weight-loss drug, marketed under the name Redux.

Plaintiffs allege that defendants knew or recklessly disregarded material facts showing that Redux had been linked in Europe to heart-valve damage, and that defendants knew of or recklessly disregarded adverse-reaction reports regarding Redux that showed conditions linked to heart-valve dam[5]*5age. In addition, plaintiffs allege that in March of 1997 defendants learned of 17 cases of heart-valve damage in Fen-phen users (Fen-phen is a drug similar to Redux that was also marketed by defendants). Plaintiffs assert that these alleged omissions and/or misrepresentations caused the price of Inter-neuron common stock to drop 26%.

Plaintiffs brought suit under Sections 10(b) and 20(a) of the Securities Exchange Act, in addition to claims for negligent misrepresentation and common law fraud and deceit.

III. Procedural History

Defendants previously brought a motion to dismiss that this court denied without prejudice at the hearing of March 18, 1999. In denying the motion to dismiss, the court stated provisional findings that the plaintiffs did not meet the requirements of particularity of pleading charges of fraud or misrepresentation or nondisclosure. Rather than dismissing the action, however, the court determined that the appropriate course of action would be to allow further submissions with respect to this issue and with respect to proposed appropriate class periods and class representatives.

Defendants then filed a motion to vacate my denial of the motion to dismiss. For case management reasons, I denied that motion. I continue to hold the belief that it would be improper to dismiss this case at this time. For the reasons stated below, however, including case management reasons, I find that it is also inappropriate to certify a class unless plaintiffs meet the heightened pleading requirements necessary to sustain this class action.

IV. Motion for Class Certification

A. No Material Change from Key Elements of Plaintiffs’ Previous Position

Key elements of the plaintiffs’ position, both as presented at and before the hearing of March 18, 1999 and in the submissions filed after that hearing, are the following:

(1) Plaintiffs urge the court to certify a class of the largest conceivable breadth; and
(2) Plaintiffs urge that they not be required to comply with either the heightened pleading requirements applicable generally to claims of fraud under Federal Rules of Civil Procedure or the added requirements applicable to securities fraud litigation.

B. Adequacy of Representation and Heightened Pleading Requirements

A class cannot be certified unless an adequate class representative can be found. In instances in which one element of an asserted claim is satisfaction of heightened pleading requirements, failure to satisfy this element is fatal to a person’s claim to be an adequate representative. Plaintiffs have the burden of proving that an adequate representative exists and that a class should be certified.

As I stated on the record at the hearing of March 18, 1999, plaintiffs have repeatedly failed to plead particularized facts necessary to satisfy the heightened pleading requirements of the Federal Rules of Civil Procedure and the Private Securities Litigation Reform Act of 1995. Significant portions of the complaint are pled on information and belief, and the court cannot just accept plaintiffs’ unsupported inferences of fraudulent behavior based upon bald assertions. After lengthy discovery and numerous opportunities to state with particularity facts that sufficiently allege fraud and entity state-of-mind, plaintiffs continue to fail to identify any particular person with knowledge of a particular fraud.

None of the claims asserted meets the heightened pleading requirements. Thus, none of the proposed representatives has brought claims on which that person could adequately represent the proposed class. Plaintiffs have not shown that any of the representatives has a viable claim because they have not specified any fraud as to which any person would be able to offer proof within the scope of that specifically alleged fraud. The plaintiffs must plead the factual elements of a fraud with particularity, and plead that a particular person among the proposed class representatives can prove that she or he suffered a loss from that particularized fraud. If plaintiffs fail to sat[6]*6isfy these pleading requirements, it is inappropriate to certify a class at this time. Plaintiffs’ failure to meet the specificity of pleading requirement is so complete that no identifiable person has been alleged to be capable of meeting the requirement. This posture of the record leaves in grave doubt whether any such person exists.

C. Proposed Inferences and Presumptions

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Thomas v. Moreland
District of Columbia, 2022
In re Sonus Networks, Inc. Securities Litigation
247 F.R.D. 244 (D. Massachusetts, 2007)
In Re Ikon Office Solutions, Inc. Securities Litigation
66 F. Supp. 2d 622 (E.D. Pennsylvania, 1999)

Cite This Page — Counsel Stack

Bluebook (online)
188 F.R.D. 3, 44 Fed. R. Serv. 3d 1179, 1999 U.S. Dist. LEXIS 8948, 1999 WL 395340, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-interneuron-pharmaceuticals-litigation-mad-1999.